Company Research Report: ARTBIO
Company Overview
Name
ARTBIO Inc.
Mission
ARTBIO is redefining cancer care by developing a new class of alpha radioligand therapies (ART) and building the ecosystem that maximizes their potential.
Founding
ARTBIO was founded in 2021 by Roy Larsen and Øyvind Bruland, rooted in pioneering research conducted at the University of Oslo and Norway’s Radium Hospital.
Key People
- Emanuele Ostuni, PhD: Founding CEO
- Nick Pullen, PhD: Chief Scientific Officer
- Philippe Dasse, PharmD: Chief Technical Officer
- Conrad Wüller, MSc: Senior Director, Strategy and Operations
- Calvin Lee, MBA: Vice President, Finance
- Vicki Jardine, MD, PhD: Vice President, Clinical Development
- Lily Bouzelmat, MSc: Vice President, Development Operations
- Jordi Vall-llosera Ferran, MSc: Senior Vice President and Global Head of Quality
- Victor Paulus, PhD: Head and Senior Vice President, Regulatory Affairs
- Daniel Rossetto, MSc: Head & SVP, Supply Chain and External Manufacturing
- Tanja Aarvak, PhD: Director, Drug Product Development and Manufacturing
- Gjermund Fjeld Olsen, MSc: Director, Generator Development and Manufacturing
- Bharat Lagu, PhD: Senior Vice President, Discovery
- Ada Repetto-Llamares, PhD: Director, Translational Biology
- Phil Ruis, PhD: Director, Partnered Discovery and Business Development
- Kate Devlin Rushton: Vice President, Human Resources
- Ivana Galetic, PhD: Senior Vice President, Program Management
- Sanjay Sharma, MSc, CRadPhr, PhD: Vice President, CMC Operations and Development
Headquarters
- U.S. Headquarters: ARTBIO Inc., c/o Alexandria LaunchLabs, One Kendall Sq, B200, Suite 001, Cambridge, MA 02139
Global Locations
- Switzerland: Aeschengraben 9, 4051 Basel, Switzerland
- Norway: Kjelsåsveien 168 B, 0884 Oslo, Norway
- UK (Office): The Harley Building, 77 New Cavendish St, London W1W 6XB, UK
- UK (Outreach & Shipments): 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, WA14 2DT, UK
Number of Employees
No information is available.
Revenue
No information is available.
Known For
ARTBIO is known for developing targeted alpha radioligand therapies (ARTs) to redefine cancer care with a focus on patient-centric solutions and a legacy of pioneering work in radiation therapy.
Products
Pipeline Products
ARTBIO is focused on developing alpha radioligand therapies with an optimal alpha-precursor isotope, Pb212. Their ARTs are characterized by high affinity and selectivity, effectively targeting tumor cells while sparing healthy tissues.
Lead Product
- AB001: Targeting Prostate Cancer, currently in Phase 0 Clinical Trials.
Additional Pipeline Programs
- ABA: Targets multiple solid tumors, details undisclosed.
- ABB: Targets multiple solid tumors, details undisclosed.
- ABC: Targets multiple solid tumors, details undisclosed.
Key Features
- Use of the ideal isotope, Pb212, known for its effective energy delivery and imaging capabilities.
- ART manufacturing utilizes the AlphaDirect™ platform for distributed production and delivery.
- Combines expertise in oncology, radiology, and drug development for innovative cancer therapies.
Recent Developments
New Partnerships and Collaborations
1. Collaboration with Oslo University Hospital:
- Announced a partnership to advance the research and development of ARTs.
- Focuses on mechanistic understanding of 212Pb-based radiopharmaceuticals (June 5, 2024).
2. Partnership with FogPharma:
- Co-develop Helicon™-enabled alpha-particle radioligand therapies for cancer treatment.
- Combined proprietary platforms aim to maximize therapeutic efficacy (May 14, 2024).
3. Collaboration with Nucleus RadioPharma:
- Manufacturing agreement to support clinical trials of ARTBIO's 212Pb-radiolabeled therapies, particularly AB001 (May 7, 2024).
4. Strategic Partnership with AlphaGen Therapeutics:
- Exclusive collaboration to develop and commercialize AB001 in Greater China.
- ARTBIO granted AlphaGen rights to use AlphaDirect™ technology (February 20, 2024).
New Product Features
- Introduction of AlphaDirect™, a proprietary technology method for 212Pb isolation that enhances drug delivery mechanisms and manufacturing processes.
Recent Initiatives
- Progression of lead program AB001 into first in human trials.
- Expansion of ART manufacturing ecosystems to ensure rapid accessibility.
